Transgene Biotek Ltd (526139)

Transgene Biotek's Board approved the appointment of M/s. Harish Gummadi & Co. as Statutory Auditors on November 02, 2026, to fill a casual vacancy. This follows the resignation of M/s. Eswara Rao & Co. on October 28, 2026, who cited partner medical emergencies just 18 days after their own appointment on October 10, 2026. The outgoing auditors confirmed no audit or limited review work had commenced and reported no management non-cooperation. The new appointment is valid until the conclusion of the upcoming Annual General Meeting and remains subject to shareholder approval.

• Appointment of M/s. Harish Gummadi & Co. (FRN: 023771S) approved on November 02, 2026
• Preceding auditor M/s. Eswara Rao & Co. resigned on October 28, 2026, after serving just 18 days
• Eswara Rao & Co. had been appointed on October 10, 2026, following the exit of M/s. Vasavi & Co.
• Outgoing auditors reported nil limited review or audit work completed prior to resignation
• Shareholder approval for the appointment to be sought at a general meeting within 3 months

Transgene Biotek's Board approved the appointment of M/s. Eswara Rao & Co., Chartered Accountants, as Statutory Auditors on October 10, 2026. This appointment fills a casual vacancy created by the resignation of M/s. Vasavi & Co., Chartered Accountants. The appointment remains subject to approval by shareholders at an upcoming general meeting. Transgene Biotek reported annual revenue of ₹0.20 crore and a net loss of ₹1.65 crore for FY26.

• Appointment of M/s. Eswara Rao & Co. (FRN: 000816S) approved on October 10, 2026
• Casual vacancy caused by the resignation of outgoing auditors M/s. Vasavi & Co.
• Partner Karra Pranavi (Membership No. 232994) to represent the statutory audit firm
• Board meeting commenced at 11:00 AM and concluded at 12:30 PM on October 10, 2026

Transgene Biotek Ltd has submitted an intimation confirming the non-applicability of Regulation 32(1) of SEBI Listing Regulations for the quarter ended September 30, 2026. The company stated that no public issue, rights issue, or preferential issue was conducted during the reporting quarter. Consequently, a Statement of Deviation or Variation is not required. The company noted that it filed via PDF as the XBRL mode does not permit NIL entries.

• Regulation 32(1) Statement of Deviation or Variation is not applicable for the quarter ended September 30, 2026
• No funds were raised via public issue, rights issue, or preferential issue during the quarter ended September 30, 2026
• Company cited an inability to submit via XBRL mode because the system does not allow NIL entries
• Intimation submitted to BSE on October 3, 2026

Transgene Biotek has submitted a regulatory intimation confirming the non-applicability of Regulation 57(5) of SEBI LODR for the quarter ended September 30, 2026. The company stated that it has no non-convertible securities issued, meaning there are no interest, dividend, or principal payment obligations due. Transgene Biotek remains a micro-cap entity (market cap ₹21 Cr) with negative net worth of ₹-9 Cr and negligible TTM revenue. This filing represents purely routine quarterly compliance.

• Filing confirms Regulation 57(5) of SEBI LODR is not applicable for quarter ended September 30, 2026
• Company has zero issued non-convertible securities
• No interest, dividend, or principal repayment obligations due or unpaid during the period

Transgene Biotek has scheduled a board meeting for August 07, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. A key agenda item is the proposal to seek an extension for holding the Annual General Meeting (AGM) for FY 2025-26. The company is currently in a precarious financial position with a TTM revenue of nearly zero and a high Debt-to-Equity ratio of 2.05. Investors should note the appointment of a new internal auditor for FY 2026-27 as part of the meeting's agenda.

• Board meeting scheduled for August 07, 2026, to approve Q1 FY27 results.
• Company seeking an extension for the Annual General Meeting (AGM) for the financial year 2025-26.
• Appointment of internal auditor for the financial year 2026-27 to be considered.
• Trading window closed from July 01, 2026, until 48 hours after results are made public.
• Company reported a net loss of Rs 0.46 Cr in the most recent quarter (March 2026).

Transgene Biotek has filed a compliance report stating that SEBI Regulation 57(4) is not applicable for the quarter ended June 30, 2026. The company confirmed it has no outstanding non-convertible securities for which interest, dividend, or principal payments were due during this period. This is a routine administrative filing for companies without listed debt instruments. Financially, the company remains in a stressed position with a TTM net loss of Rs 2 Cr and a high debt-to-equity ratio of 2.05.

• Regulation 57(4) declared not applicable for the quarter ended 30.06.2026
• Zero non-convertible securities currently require interest or principal payments
• Company maintains a total debt of Rs 17 Cr against a net worth of Rs 8 Cr
• TTM revenue remains negligible at approximately Rs 0.26 Cr for FY25

Transgene Biotek Ltd has submitted a NIL statement of deviation or variation for the quarter ended June 30, 2026. The company confirmed that no funds were raised through public issues, rights issues, or preferential issues during this period. Consequently, Regulation 32(1) of SEBI LODR is not applicable. The filing is a standard regulatory requirement to ensure transparency in the utilization of proceeds from capital raises.

• Reporting period concluded on 30th June 2026
• Zero funds raised via public, rights, or preferential issues during the quarter
• Compliance filing under Regulation 32(1) of SEBI LODR Regulations, 2015
• Company noted technical inability to file via XBRL due to NIL entry restrictions